Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting

BERKELEY, CA, November 3, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining […]

Article Date

This article is featured on another website.

Go to article